Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3.

Scharla SH, Minne HW, Waibel-Treber S, Schaible A, Lempert UG, Wüster C, Leyendecker G, Ziegler R

The Journal of clinical endocrinology and metabolism1 Apr 1990Cited by 40 (Europe PMC)

PMID2138629DOI10.1210/jcem-70-4-1055PepBankPUB-02138629

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialSafety outcome
In women receiving decapeptyl, alkaline phosphatase increased after estrogen deficiency began.
In plain wordsIn women receiving decapeptyl, alkaline phosphatase increased after estrogen deficiency began.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAlkaline phosphatase
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Our results showed an increase in bone turnover after initiation of estrogen deficiency, as indicated by the elevation of alkaline phosphatase and osteocalcin.
3 context sentences(design, population, supporting numbers)
Summary · context
In search for factors, conditioning the response of bone to estrogen deficiency, we have conducted a study in females under treatment with the GnRH agonist decapeptyl (D-Trp6-LHRH).
Summary · context
This drug blocks ovarian function and was administered for treatment of endometriosis or uterine leiomyoma.
Summary · context
We determined spinal (dual photon absorptiometry) and forearm (single photon absorptiometry) bone mineral density before and 3 and 6 months after the onset of therapy and measured biochemical parameters of bone metabolism.
Report a problemFND-0213862902
02HumanNon-randomized trialSafety outcome
In women receiving decapeptyl, osteocalcin increased after estrogen deficiency began.
In plain wordsIn women receiving decapeptyl, osteocalcin increased after estrogen deficiency began.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseOsteocalcin
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Our results showed an increase in bone turnover after initiation of estrogen deficiency, as indicated by the elevation of alkaline phosphatase and osteocalcin.
3 context sentences(design, population, supporting numbers)
Summary · context
In search for factors, conditioning the response of bone to estrogen deficiency, we have conducted a study in females under treatment with the GnRH agonist decapeptyl (D-Trp6-LHRH).
Summary · context
This drug blocks ovarian function and was administered for treatment of endometriosis or uterine leiomyoma.
Summary · context
We determined spinal (dual photon absorptiometry) and forearm (single photon absorptiometry) bone mineral density before and 3 and 6 months after the onset of therapy and measured biochemical parameters of bone metabolism.
Report a problemFND-0213862903
03HumanNon-randomized trialSafety outcome
In women receiving decapeptyl, serum intact PTH decreased following increased bone turnover.
In plain wordsIn women receiving decapeptyl, serum intact PTH decreased following increased bone turnover.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum intact PTH
Study
n: not reported in source
Outcome group
Bone and joint · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
This resulted in a secondary decrease in serum intact PTH and 1,25-dihydroxy-vitamin D3.
4 context sentences(design, population, supporting numbers)
Summary · context
Our results showed an increase in bone turnover after initiation of estrogen deficiency, as indicated by the elevation of alkaline phosphatase and osteocalcin.
Summary · context
In search for factors, conditioning the response of bone to estrogen deficiency, we have conducted a study in females under treatment with the GnRH agonist decapeptyl (D-Trp6-LHRH).
Summary · context
This drug blocks ovarian function and was administered for treatment of endometriosis or uterine leiomyoma.
Summary · context
We determined spinal (dual photon absorptiometry) and forearm (single photon absorptiometry) bone mineral density before and 3 and 6 months after the onset of therapy and measured biochemical parameters of bone metabolism.
Report a problemFND-0213862904
04HumanNon-randomized trialSafety outcome
In women receiving decapeptyl, serum 1,25-dihydroxyvitamin D3 decreased following increased bone turnover.
In plain wordsIn women receiving decapeptyl, active vitamin D levels decreased following increased bone turnover.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum 1,25-dihydroxyvitamin D3
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
This resulted in a secondary decrease in serum intact PTH and 1,25-dihydroxy-vitamin D3.
4 context sentences(design, population, supporting numbers)
Summary · context
Our results showed an increase in bone turnover after initiation of estrogen deficiency, as indicated by the elevation of alkaline phosphatase and osteocalcin.
Summary · context
In search for factors, conditioning the response of bone to estrogen deficiency, we have conducted a study in females under treatment with the GnRH agonist decapeptyl (D-Trp6-LHRH).
Summary · context
This drug blocks ovarian function and was administered for treatment of endometriosis or uterine leiomyoma.
Summary · context
We determined spinal (dual photon absorptiometry) and forearm (single photon absorptiometry) bone mineral density before and 3 and 6 months after the onset of therapy and measured biochemical parameters of bone metabolism.
Report a problemFND-0213862905

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In women treated with decapeptyl, higher pretreatment serum 1,25-dihydroxyvitamin D3, and its larger decrease, correlated positively with greater bone mass reduction.
In plain wordsIn women treated with decapeptyl, higher pretreatment active vitamin D levels and bigger drops in it were linked to greater bone mass loss.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableAssociation of pretreatment 1,25-dihydroxyvitamin D3 with bone mass reduction
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Furthermore, we found a positive correlation between pretreatment values of serum 1,25-dihydroxyvitamin D3 as well as its decrease and the reduction in bone mass during GnRH agonist treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
In search for factors, conditioning the response of bone to estrogen deficiency, we have conducted a study in females under treatment with the GnRH agonist decapeptyl (D-Trp6-LHRH).
Summary · context
This drug blocks ovarian function and was administered for treatment of endometriosis or uterine leiomyoma.
Summary · context
We determined spinal (dual photon absorptiometry) and forearm (single photon absorptiometry) bone mineral density before and 3 and 6 months after the onset of therapy and measured biochemical parameters of bone metabolism.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0213862906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.